AIMS/HYPOTHESIS: To determine if the haptoglobin 2 allele is associated with an increased risk for the development of diabetic nephropathy. METHODS: This study included 110 consecutive normotensive subjects with Type I (insulin-dependent) diabetes mellitus and Type II (non-insulin-dependent) diabetes mellitus seen in two outpatient clinics in Israel. Diabetes duration was greater than 10 years for Type I diabetes and more than 5 years for Type II diabetic subjects. Microalbuminuria was defined as urinary protein excretion of 30 to 300 mg/24 h, and macroalbuminuria was defined as urinary protein excretion of greater than 300 mg/24 h. Serum was taken from subjects for haptoglobin typing by gel electrophoresis. RESULTS: Of the participating subjects 54 had Type I and 56 had Type II diabetes. None (0/18) of the subjects homozygous for the haptoglobin 1 allele (1-1) showed any sign of diabetic nephropathy, as compared with 34 % (19/55) of subjects homozygous for the haptoglobin 2 allele (2-2) and 27 % (10/37) of heterozygous subjects (2-1) (p < 0.04). Of the subjects 29 showed macroalbuminuria. The risk of developing macroalbuminuria was found to be greater in subjects with two haptoglobin 2 alleles (22 %) (12/55) as compared with one haptoglobin 2 allele (8 %) (3/37) or no haptoglobin 2 alleles (0%) (0/18) (p < 0.03). CONCLUSION/ INTERPRETATION: By showing a graded risk relation to the number of haptoglobin 2 alleles in Type I and Type II diabetic subjects, these studies further support our hypothesis that the haptoglobin phenotype is a major susceptibility gene for the development of diabetic nephropathy.
AIMS/HYPOTHESIS: To determine if the haptoglobin 2 allele is associated with an increased risk for the development of diabetic nephropathy. METHODS: This study included 110 consecutive normotensive subjects with Type I (insulin-dependent) diabetes mellitus and Type II (non-insulin-dependent) diabetes mellitus seen in two outpatient clinics in Israel. Diabetes duration was greater than 10 years for Type I diabetes and more than 5 years for Type II diabetic subjects. Microalbuminuria was defined as urinary protein excretion of 30 to 300 mg/24 h, and macroalbuminuria was defined as urinary protein excretion of greater than 300 mg/24 h. Serum was taken from subjects for haptoglobin typing by gel electrophoresis. RESULTS: Of the participating subjects 54 had Type I and 56 had Type II diabetes. None (0/18) of the subjects homozygous for the haptoglobin 1 allele (1-1) showed any sign of diabetic nephropathy, as compared with 34 % (19/55) of subjects homozygous for the haptoglobin 2 allele (2-2) and 27 % (10/37) of heterozygous subjects (2-1) (p < 0.04). Of the subjects 29 showed macroalbuminuria. The risk of developing macroalbuminuria was found to be greater in subjects with two haptoglobin 2 alleles (22 %) (12/55) as compared with one haptoglobin 2 allele (8 %) (3/37) or no haptoglobin 2 alleles (0%) (0/18) (p < 0.03). CONCLUSION/ INTERPRETATION: By showing a graded risk relation to the number of haptoglobin 2 alleles in Type I and Type II diabetic subjects, these studies further support our hypothesis that the haptoglobin phenotype is a major susceptibility gene for the development of diabetic nephropathy.
Authors: Michael B Adinortey; Ben A Gyan; Jonathan P Adjimani; Philomena E Nyarko; Charity Sarpong; Francis Y Tsikata; Alexander K Nyarko Journal: Indian J Clin Biochem Date: 2011-05-13
Authors: V Eric Kerchberger; Julie A Bastarache; Ciara M Shaver; Hiromasa Nagata; J Brennan McNeil; Stuart R Landstreet; Nathan D Putz; Wen-Kuang Yu; Jordan Jesse; Nancy E Wickersham; Tatiana N Sidorova; David R Janz; Chirag R Parikh; Edward D Siew; Lorraine B Ware Journal: JCI Insight Date: 2019-11-01
Authors: Xunde Wang; Jose E Tanus-Santos; Christopher D Reiter; Andre Dejam; Sruti Shiva; Reginald D Smith; Neil Hogg; Mark T Gladwin Journal: Proc Natl Acad Sci U S A Date: 2004-07-16 Impact factor: 11.205
Authors: Marie-Christine W Gast; Harm van Tinteren; Marijke Bontenbal; René Q G C M van Hoesel; Marianne A Nooij; Sjoerd Rodenhuis; Paul N Span; Vivianne C G Tjan-Heijnen; Elisabeth G E de Vries; Nathan Harris; Jos W R Twisk; Jan H M Schellens; Jos H Beijnen Journal: BMC Cancer Date: 2008-12-24 Impact factor: 4.430